newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

  • IGC Pharma filed its Q1 2026 Form 10-Q with the SEC on May 19, 2026.
  • The Phase 2 CALMA trial for IGC-AD1 continues with a target enrollment of 146 patients & approximately 80% enrollment achieved subsequent to March 2026.
  • New clinical sites were added to the CALMA network, including Dominion Medical Associates, Integrative Clinical Trials, & Visionary Investigators Network.
  • Utility patent applications were filed for the AHA AI-based data harmonization system architecture.
  • The Canadian Intellectual Property Office issued a Notice of Allowance for the proprietary composition of IGC-AD1.
  • R&D expenses rose to approximately $1.3 million due to CALMA trial progression.
  • Revenue was $317 thousand, primarily from the Life Sciences segment's white-labeled product sales.
  • SG&A expenses increased to approximately $1.2 million, largely due to the absence of a $700 thousand bonus conversion credit from the prior year.
  • Net loss for the quarter was approximately $2.4 million, with a loss per share of $0.02.
  • Total outstanding debt stood at $917 thousand as of March 31, 2026, with an additional $585 thousand raised subsequently.
  • The company retains access to an undrawn $12 million O-Bank credit facility & is evaluating further financing options.